ABSI logo

Absci Corporation (ABSI)

$7.58

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ABSI

Market cap

$1.31B

EPS

-0.78

P/E ratio

--

Price to sales

1116.98

Dividend yield

--

Beta

2.229692

Price on ABSI

Previous close

$7.48

Today's open

$7.57

Day's range

$7.34 - $7.79

52 week range

$2.24 - $12.54

Profile about ABSI

CEO

Sean Mcclain

Employees

140

Headquarters

Vancouver, WA

Exchange

Nasdaq Global Select

Shares outstanding

172745810

Issue type

Common Stock

ABSI industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ABSI

Absci Q3 Earnings Call Highlights

Absci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's third-quarter business update on November 12.

news source

MarketBeat • Nov 12, 2026

news preview

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month

news source

GlobeNewsWire • Nov 12, 2026

news preview

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline

Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK

news source

GlobeNewsWire • Nov 12, 2026

news preview

Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

news source

Seeking Alpha • Nov 11, 2026

news preview

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference (Boston, MA) Fireside chat on Tuesday, November 10th at 1:00 p.m.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.

news source

GlobeNewsWire • Oct 13, 2026

news preview

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.

news source

GlobeNewsWire • Sep 24, 2026

news preview

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Absci Corporation

Open an M1 investment account to buy and sell Absci Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ABSI on M1